These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
    Author: Fløe LE, Svane IM, Bastholt L, Schmidt H.
    Journal: Ugeskr Laeger; 2016 Aug 15; 178(33):. PubMed ID: 27550784.
    Abstract:
    The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.
    [Abstract] [Full Text] [Related] [New Search]